KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Leases: 2020-2025

Historic Current Leases for Aquestive Therapeutics (AQST) over the last 6 years, with Sep 2025 value amounting to $601,000.

  • Aquestive Therapeutics' Current Leases rose 24.69% to $601,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $601,000, marking a year-over-year increase of 24.69%. This contributed to the annual value of $510,000 for FY2024, which is 30.77% up from last year.
  • Aquestive Therapeutics' Current Leases amounted to $601,000 in Q3 2025, which was up 5.44% from $570,000 recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Current Leases high stood at $926,000 for Q1 2022, and its period low was $255,000 during Q4 2022.
  • For the 3-year period, Aquestive Therapeutics' Current Leases averaged around $454,909, with its median value being $455,000 (2024).
  • Its Current Leases has fluctuated over the past 5 years, first slumped by 71.64% in 2022, then soared by 52.94% in 2023.
  • Aquestive Therapeutics' Current Leases (Quarterly) stood at $899,000 in 2021, then slumped by 71.64% to $255,000 in 2022, then spiked by 52.94% to $390,000 in 2023, then soared by 30.77% to $510,000 in 2024, then rose by 24.69% to $601,000 in 2025.
  • Its last three reported values are $601,000 in Q3 2025, $570,000 for Q2 2025, and $540,000 during Q1 2025.